JP2020022459A5 - - Google Patents

Download PDF

Info

Publication number
JP2020022459A5
JP2020022459A5 JP2019169775A JP2019169775A JP2020022459A5 JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5 JP 2019169775 A JP2019169775 A JP 2019169775A JP 2019169775 A JP2019169775 A JP 2019169775A JP 2020022459 A5 JP2020022459 A5 JP 2020022459A5
Authority
JP
Japan
Prior art keywords
seq
adenovirus
vector
transgene
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019169775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020022459A (ja
JP7394285B2 (ja
Filing date
Publication date
Priority claimed from JP2018137237A external-priority patent/JP6970647B2/ja
Application filed filed Critical
Publication of JP2020022459A publication Critical patent/JP2020022459A/ja
Publication of JP2020022459A5 publication Critical patent/JP2020022459A5/ja
Application granted granted Critical
Publication of JP7394285B2 publication Critical patent/JP7394285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019169775A 2011-10-05 2019-09-18 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法 Active JP7394285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543661P 2011-10-05 2011-10-05
US61/543,661 2011-10-05
JP2018137237A JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018137237A Division JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Publications (3)

Publication Number Publication Date
JP2020022459A JP2020022459A (ja) 2020-02-13
JP2020022459A5 true JP2020022459A5 (Direct) 2020-03-26
JP7394285B2 JP7394285B2 (ja) 2023-12-08

Family

ID=47045181

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014534785A Active JP6757121B2 (ja) 2011-10-05 2012-10-05 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2019169775A Active JP7394285B2 (ja) 2011-10-05 2019-09-18 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014534785A Active JP6757121B2 (ja) 2011-10-05 2012-10-05 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法

Country Status (7)

Country Link
US (4) US9617560B2 (Direct)
EP (1) EP2764014B1 (Direct)
JP (3) JP6757121B2 (Direct)
CN (2) CN103987726B (Direct)
BR (1) BR112014008284A2 (Direct)
CA (1) CA2851251C (Direct)
WO (1) WO2013052832A2 (Direct)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850627C (en) 2011-10-05 2024-05-21 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US9617560B2 (en) 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
WO2013052799A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vectors and methods of use
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
BR112019003462A2 (pt) 2016-08-23 2019-06-25 Glaxosmithkline Biologicals Sa proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CN110036020A (zh) 2016-12-09 2019-07-19 葛兰素史密丝克莱恩生物有限公司 具有狂犬病病毒抗原的黑猩猩腺病毒构建体
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
US11649467B2 (en) 2017-07-21 2023-05-16 Glaxosmithkline Biologicals Sa Chikungunya virus antigen constructs
BR112020007695A2 (pt) * 2017-10-31 2020-10-20 Janssen Vaccines & Prevention B.V. adenovírus e seus usos
US12404306B2 (en) 2018-03-06 2025-09-02 Precigen, Inc. Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP7640538B2 (ja) 2019-10-08 2025-03-05 トラスティーズ オブ ボストン カレッジ 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
CA3170369A1 (en) 2020-03-05 2022-04-14 Michal Shahar Methods and compositions for treating cancer with immune cells
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112220921B (zh) 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
AU7264694A (en) 1993-07-13 1995-02-13 Rhone-Poulenc Rorer S.A. Defective adenovirus vectors and use thereof in gene therapy
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
WO1997000326A1 (en) 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU2249097A (en) 1996-01-29 1997-08-20 Georgetown University Malaria vaccine based upon the addition of a msa1 peptide
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
WO2003020879A2 (en) 2001-07-23 2003-03-13 Genvec, Inc. Cells and methods for propagating adenoviral vectors
WO2003022311A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
JP4621743B2 (ja) 2004-12-13 2011-01-26 カンジ,インコーポレイテッド 複製欠損アデノウイルスの産生のための細胞株
DE102005006388A1 (de) * 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
EP1929021A2 (en) 2005-08-31 2008-06-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
SG172935A1 (en) 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
RU2012107702A (ru) 2009-07-31 2013-09-10 Пэксвэкс, Инк. Векторы на основе аденовирусов
KR20120139672A (ko) * 2009-11-09 2012-12-27 젠벡, 인코포레이티드 원숭이 아데노바이러스 벡터의 증식 방법
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
CA2850627C (en) * 2011-10-05 2024-05-21 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
WO2013052799A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vectors and methods of use
EP2764011B1 (en) * 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
US9617560B2 (en) 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
EP2809346A1 (en) * 2012-02-02 2014-12-10 GenVec, Inc. Adenoviral vector-based malaria vaccine
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine

Similar Documents

Publication Publication Date Title
JP2020022459A5 (Direct)
JP2018520997A5 (Direct)
JP2023082054A5 (Direct)
JP2010227108A5 (Direct)
JP2021112211A5 (Direct)
JP2019214579A5 (Direct)
JP2010065037A5 (Direct)
JP2020505025A5 (Direct)
JP2016537341A5 (Direct)
JP2010088434A5 (Direct)
JP2019522461A5 (Direct)
JP2012505657A5 (Direct)
JP2019528793A5 (Direct)
JP2016146837A5 (Direct)
JP2016501531A5 (Direct)
JP2011087580A5 (Direct)
JP2003514526A5 (Direct)
JP2017534262A5 (Direct)
JP2010532978A5 (Direct)
JP2008525033A5 (Direct)
JP2010534684A5 (Direct)
JP2011155981A5 (Direct)
RU2019144161A (ru) Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы и их применения
RU2015135890A (ru) Композиция вакцины
JP2015533791A5 (Direct)